Molecular interactions and functional interference between vitronectin and transforming growth factor-β

Laboratory Investigation

Volumn 82, Issue 1, 2002, Pages 37-46

  Schoppet, Michael ^a   Chavakis, Triantafyllos ^a   Al Fakhri, Nadia ^a   Kanse, Sandip M ^a   Preissner, Klaus T ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BASIC FIBROBLAST GROWTH FACTOR; BINDING PROTEIN; EPIDERMAL GROWTH FACTOR; GLYCOPROTEIN; GROWTH FACTOR; MATRIX PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SYNTHETIC PEPTIDE; THROMBIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; VITRONECTIN;

AMINO TERMINAL SEQUENCE; ARTICLE; ATHEROSCLEROSIS; BINDING SITE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; LUNG ALVEOLUS EPITHELIUM; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; B-LYMPHOCYTES; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXTRACELLULAR MATRIX; FIBRONECTINS; HUMANS; KINETICS; MICE; PROTEIN BINDING; PROTEIN ISOFORMS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VITRONECTIN;

EID: 0036141827     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780393     Document Type: Article

References (54)

1. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promotor-luciferase construct
2. Characterization of changes induced by treatment with urea
3. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions
4. 2-integrins
5. Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy
6. Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells
7. 2-macroglobulin
8. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma: Identification as a multimeric form of S-protein (vitronectin)
9. Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque
10. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice
11. Vitronectin interaction with glycosaminoglycans
12. Localization of transforming growth factor β binding site in betaglycan: Comparison with small extracellular matrix proteoglycans
13. Phosphorylation of vitronectin on Ser362 by protein kinase C attenuates its cleavage by plasmin
14. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-β1
15. TGF-β in blood: A complex problem
16. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β
17. 2-macroglobulin
18. Increased intraplatelet and urinary transforming growth factor-β in patients with multiple myeloma
19. Fibronectin, not laminin, mediates heparin-dependent heparin-binding growth factor type I binding to substrata and stimulation of endothelial cell growth
20. Plasminogen activator inhibitor-1 represses integrin-mediated cell migration independently of its function as an inhibitor of plasminogen activation
21. A dual receptor system is required for basic fibroblast growth factor activity
22. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice
23. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation
24. Vitronectin and plasmin(ogen) in lesional skin of the bullous pemphigoid: Colocalization suggests binding interactions
25. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
26. 125I-labelled fibrinogen in normal rabbits and in rabbits with indwelling intravenous catheters: Methodologic aspects
27. The transforming growth factor-β family
28. TGF-β signal transduction
29. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells
30. Transforming growth factor β-1 binds to immobilized fibronectin
31. The 66, 56, 50 and 47 kDa vitronectins in atherosclerotic lesions and in serum
32. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease
33. Latent transforming growth factor-β: Structural features and mechanisms of activation
34. Transforming growth factor-β complexes with thrombospondin
35. Vascular endothelial growth factor (VEGF) and its receptors
36. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction
37. Transforming growth factor β type 1 binds to collagen IV of basement membrane matrix: Implications for development
38. Structure and biological role of vitronectin
39. Identification and partial characterization of platelet vitronectin: Evidence for complex formation with platelet-derived plasminogen activator inhibitor-1
40. Physicochemical characterization of human S-protein and its function in the blood coagulation system
41. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptor
42. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation
43. Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding
44. Phosphorylation of vitronectin by casein kinase II
45. vβ3 binding to vitronectin
46. Multimeric vitronectin
47. Inhibition of endothelial cell growth by macrophage-like U-937 cell-derived oncostatin M, leukemia inhibitory factor, and transforming growth factor β1
48. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
49. Identification of vitronectin as a novel insulin-like growth factor-II binding protein
50. Localization of vitronectin in the normal and atherosclerotic human vessel wall
51. Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease
52. vβ3/ligand interactions using a [3H]SK&F-107260 binding assay
53. Negative regulation of transforming growth factor-β by the proteoglycan decorin
54. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor